Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Add to Basket
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN251660

Fms-Related tyrosine Kinase 1 (Vascular Endothelial Growth Factor/vascular Permeability Factor Receptor)/kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (FLT1/KDR) antibody

Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Clonality Polyclonal
Flow Cytometry (FACS), Western Blotting (WB)
Pubmed 3 references available
Catalog no. ABIN251660
Quantity 25 µL
Contact our Customer Service for availability and price in your country.
Shipping to
Immunogen A synthetic peptide made to an internal region of the murine VEGFR1 protein sequence(between residues 800-900). There is 87% identity between the immunogen used forthis production and the VEGFR-2 protein.
Specificity This antibody is specific for VEGFR-1 with significant cross-reactivity with the VEGFR-2protein. Species Reactivity: This antibody reacts with human protein. Other species have not yet been tested. Theimmunogen used for this antibody production has 100% homology with mouse, rat andhuman VEGFR-1 proteins. Localization: Type 1 membrane protein (isoform Flt1).
Alternative Name VEGFR-1/2
Background Receptors for VEGF, VEGFB and PGF have a tyrosine-protein kinase activity. TheVEGF-kinase ligand/receptor signaling system plays a key role in vascular developmentand regulation of vascular permeability. VEGF and its high-affinity binding receptors, the tyrosine kinases FLK1 and FLT1, arethought to be important for the development of embryonic vasculature. It has beenshown that an alternately spliced form of FLT1 produces a soluble protein, termedsFLT1, which binds vascular endothelial growth factor with high affinity, playing aninhibitory role in angiogenesis. Alternate Names: anti-VEGFR1 antibody, anti-VEGFR 1 antibody, anti-Vascular permeability factorreceptor antibody, anti-Tyrosine-protein kinase receptor FLT antibody, anti-Flt-1antibody, anti-Tyrosine-protein kinase FRT antibody, anti-Fms-like tyrosine kinase 1antibody, anti-Embryonic receptor kinase 2 antibody, anti-VEGFR2 antibody,anti-VEGFR 2 antibody, anti-Protein-tyrosine kinase receptor flk-1 antibody, anti-Fetalliver kinase 1 antibody, anti-Kinase NYK antibody, anti-FLK1 antibody, anti-KDRantibody, anti-Kinase insert domain receptor antibody, anti-KRD1 antibody, anti-Ly73antibody, anti-Protein tyrosine kinase receptor FLK1 antibody, anti-Vascular endothelialgrowth factor receptor 2 antibody.
Application Notes This antibody is useful for Western blot analysis, where a band is seen at ~180-230 kDa(the theoretical molecular weight of mouse VEGFR1 is ~150 kDa and human VEGFR1is ~151 kDa). The difference in MWs is likely due to glycosylation or other posttranslational modifications. With CSF-1R/VEGFR2 chimera transfected lysates adoublet is seen at ~150 kDa representing VEGFR-2. An unknown band is also seen at~50 kDa.Suggested Starting Dilution:*Western Blot: 1:250-1:1,000 (ECL)*Optimal working dilutions should be determined by the investigator.
Restrictions For Research Use only
Concentration 1 mg/ml
Buffer Tris-glycine, 150mM NaCl. Preservative: 0.05% sodium azide.
Preservative Sodium azide
Storage 4 °C
Rahimi, Dayanir, Lashkari: "Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells." in: The Journal of biological chemistry, Vol. 275, Issue 22, pp. 16986-92, 2000 (PubMed).

Gluzman-Poltorak, Cohen, Shibuya et al.: "Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes." in: The Journal of biological chemistry, Vol. 276, Issue 22, pp. 18688-94, 2001 (PubMed).

Takahashi, Hattori, Iwamatsu et al.: "A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1." in: The Journal of biological chemistry, Vol. 279, Issue 44, pp. 46304-14, 2004 (PubMed).